-inc-logo-1200x675.jpg?v=20240515130629){kind=logo}
Definium Therapeutics (NASDAQ:DFTX – Get Free Report) had its price target hoisted by equities researchers at Robert W. Baird from $75.00 to $79.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s price target points to a potential upside of 96.27% from the stock’s previous close.
DFTX has been the topic of several other research reports. Canaccord Genuity Group set a $64.00 price objective on shares of Definium Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 13th. Stifel Nicolaus upped their price objective on shares of Definium Therapeutics from $30.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Citigroup reissued a “buy” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Wells Fargo & Company raised their target price on Definium Therapeutics from $68.00 to $72.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. Finally, Maxim Group set a $55.00 price target on Definium Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 14th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $63.60.
Check Out Our Latest Stock Report on DFTX
Definium Therapeutics Stock Performance
Definium Therapeutics (NASDAQ:DFTX – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). On average, sell-side analysts anticipate that Definium Therapeutics will post -3.02 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, CEO Robert Barrow sold 19,023 shares of the company’s stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $37.94, for a total value of $721,732.62. Following the completion of the transaction, the chief executive officer directly owned 1,494,640 shares in the company, valued at approximately $56,706,641.60. This represents a 1.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Mark Sullivan sold 13,008 shares of the stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $585,750.24. Following the completion of the transaction, the insider owned 320,571 shares of the company’s stock, valued at approximately $14,435,312.13. This represents a 3.90% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 67,119 shares of company stock valued at $2,887,496 over the last ninety days. 2.40% of the stock is owned by insiders.
Institutional Investors Weigh In On Definium Therapeutics
A number of large investors have recently bought and sold shares of the business. Sequoia Financial Advisors LLC acquired a new stake in shares of Definium Therapeutics in the second quarter valued at approximately $812,000. WINTON GROUP Ltd bought a new position in Definium Therapeutics in the second quarter valued at about $240,000. Engineers Gate Manager LP bought a new stake in Definium Therapeutics during the 2nd quarter worth about $481,000. Integrated Wealth Concepts LLC bought a new position in shares of Definium Therapeutics in the 2nd quarter valued at about $159,000. Finally, NewEdge Advisors LLC bought a new stake in shares of Definium Therapeutics during the second quarter worth approximately $222,000. 27.91% of the stock is currently owned by institutional investors.
Trending Headlines about Definium Therapeutics
Here are the key news stories impacting Definium Therapeutics this week:
- Positive Sentiment: Second Phase 3 success: Definium said its Panorama Phase 3 study met its primary endpoint, showing a statistically significant improvement in anxiety symptoms among patients with GAD. Management characterized the data as unusually strong, driving reports of a sharp gain in DFTX shares. Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study
- Positive Sentiment: Commercial and regulatory expectations improved: Success in a second late-stage GAD trial reduces clinical-development risk and may support Definium’s plans to advance DT120 ODT toward regulatory submission. The results also increased investor interest in the company’s broader psychedelics-focused pipeline. Definium’s LSD-based anxiety, depression drug scores another trial win
- Positive Sentiment: Analyst support: HC Wainwright reaffirmed its “buy” rating with a $70 price target, while Needham maintained its “buy” rating and set a $66 target. Both targets imply substantial potential upside from the reference price, reinforcing the bullish reaction. Analyst rating reports
- Neutral Sentiment: News-driven volatility: Trading was briefly halted while investors awaited the clinical update, underscoring the event’s significance and DFTX’s elevated volatility. The company also granted options to three new employees covering 56,650 shares, a relatively modest potential source of dilution. Definium Therapeutics Announces New Employee Inducement Grants
- Negative Sentiment: Bearish options activity: Traders purchased 6,567 put options, about 68% above typical daily volume. This may reflect hedging after the stock’s rally or concern about elevated valuation and future volatility, although it does not necessarily indicate a directional bet.
About Definium Therapeutics
Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.
Featured Stories
- Five stocks we like better than Definium Therapeutics
- LightPath’s Defense Pivot Could Send Shares Higher
- Clearance to Climb: Why Allegiant Has Room to Fly
- 3 Defense Stocks Riding the High-Energy Laser Boom
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
Receive News & Ratings for Definium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
